BioSpace News Archive

Advanced BioCatalytics (ABC) is proud to announce that Glucospike® has been approved by the Environmental Protection Agency’s Safer Choice Program. The federal program recognizes products which have met standards for human and environmental safety. Glucospike® is one of several products in ABC’s new line of Fermactants ™ . Fe

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel a

Pulsara , the leading telehealth and communication platform that connects teams across organizations, announced today that the company has been named a compatible vendor within the American Heart Association Get With The Guidelines® program. This premier AHA program assists hospitals in measuring and improving cardiovascular diseas

The American Red Cross has elected to its National Board of Governors Brett Biggs , executive vice president and chief financial officer for Walmart Inc. The Red Cross is led by a Board of Governors wit

The American Red Cross has elected to its National Board of Governors Dave Clark , Senior Vice President, Worldwide Operations for Amazon.com. The Red Cross is led by a Board of Governors with all of th

Hoth to receive equity stake in Isoprene, full license of VNLG-152 and royalties from Isoprene for all other fields including Oncology

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillami

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced preliminary results for the first cohort of 223 subjects from its ongoing Phase 2 long-term safety study evaluating ARQ-151 (topical roflumilast cream) 0.3%

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase and sale of 2,762,430 Class B Subordinate Voting Shares of the Company (“Shares”) and warrants to purchase 1,381,215 Shares (collectively, the “Securities”) at a purchase price of US$3.62 per Share in a registered direct offering. The warrants will have an

FSD Pharma Inc. Announces US$10 Million Registered Direct Offering